Change in HER-2/neu status from negative to positive following treatment in breast cancer: A case report

Case Reports in Oncology

Volumn 4, Issue 1, 2011, Pages 19-24

  Sivarajan, Lakshmi ^a,e   Sivarajan, Kulumani M ^b   Natarelli, Joseph ^c   Aijaz, Farrukh ^d  

^a VANDERBILT UNIVERSITY   (United States)

^b Joliet Oncology and Hematology Associates   (United States)

^c Provena St Joseph's Medical Center   (United States)

^d Silver Cross Hospital   (United States)

^e Unit 421   (United States)

Author keywords

Breast cancer; Chemotherapy; HER 2 neu status; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEMCITABINE; LETROZOLE; PACLITAXEL; PROGESTERONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST BIOPSY; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BREAST CANCER; LYMPH NODE DISSECTION; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; POSTMENOPAUSE; PRIORITY JOURNAL; REPEAT PROCEDURE; TUMOR BIOPSY;

EID: 79957602587     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000324114     Document Type: Article

References (5)

1. Chang HR: Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer 2010;116:2856-2867.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182. (Pubitemid 17231334)
3. Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo AM: Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009;15:7381-7388.
4. Romond EH, Perez EA, Bryant J, Suman V, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PE, Swain SM, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684. (Pubitemid 41464706)
5. Hirata T, Shimizu C, Yonemori K, Hirakawa A, Kouno T, Tamura K, Ando M, Katsumata N, Fujiwara Y: Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br J Cancer 2009;101:1529-1536.